Genetic polymorphism of CYP2D6

Indian Journal of Pharmacology

Volumn 33, Issue 3, 2001, Pages 147-169

  Abraham, Benny K ^a,b   Adithan, C ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^b MAHATMA GANDHI UNIVERSITY   (India)

Author keywords

CYP2D6; Genetic polymorphism; Pharmacogenetics

Indexed keywords

AJMALICINE; AJMALINE; AMESERGIDE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; APRINDINE; BUDIPINE; BUFURALOL; CHLOROQUINE; CHLORPROMAZINE; CIMETIDINE; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; ENZYME INDUCING AGENT; FLECAINIDE; HALOFANTRINE; MISCELLANEOUS DRUGS AND AGENTS; NEUROLEPTIC AGENT; OPIATE DERIVATIVE; PERAZINE; QUINIDINE; THIORIDAZINE; UNINDEXED DRUG;

ALLELE; CAUCASIAN; CONCENTRATION RESPONSE; DOSE RESPONSE; DROWSINESS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; ETHNIC DIFFERENCE; GENE DUPLICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEALTH ECONOMICS; HUMAN; HYPOTENSION; METABOLIC DISORDER; PHARMACOGENETICS; PHENOTYPE; POPULATION RESEARCH; PRESCRIPTION; REVIEW; SIDE EFFECT; TOXICITY; TREATMENT FAILURE; TREMOR; XEROSTOMIA;

EID: 0034911155     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (156)

1. Genetic polymorphism of sparteine/debrisoquine oxidation: A reappraisal
2. Pharmacogenetics: 65 candles on the cake
3. Pharmacogenetics: A laboratory tool for optimizing therapeutic efficiency
4. Pharmacogenetics of antidepressants: Clinical aspects
5. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication
6. The human hepatic cytochrome P450 involved in drug metabolism
7. Human cytochromes P450: Problems and prospects
8. Polymorphic hydroxylation of debrisoquine in man
9. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
10. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population
11. "It's the genes, stupid" molecular basis and clinical consequences of genetic cytochrome P450 2D6 polymorphism
12. Dissociation of co-regulatory control of debrisoquine/phenformin and sparteine oxidation in Ghanians
13. Nomenclature for human CYP2D6 alleles
14. A nomenclature system for metabolic gene polymorphisms
15. The human debrisoquine 4-hydroxylation (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene
16. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metaboliser of the debrisoquine/sparteine polymorphism
17. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine
18. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
19. The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms
20. Molecular genetics of the debrisoquine-sparteine polymorphism
21. CYP2D6 genotype determination in the Danish population
22. Polymorphism of dextromethorphan metabolism: Relationship between phenotype, genotype, and response to the administration of encainide in humans
23. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6
24. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
25. Genetic differences in drug disposition
26. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes
27. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolisers
28. Isoform-selective metabolism of mianserin by cytochrome P450 2D
29. Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase
30. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6-the source of the sparteine/debrisoquine oxidation polymorphism
31. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance
32. Dose dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluoxamine and paroxetine
33. In vitro characterisation of the human cytochrome P450 involved in the polymorphic oxidation of propofenone
34. The influence of enzyme induction on polymorphic sparteine oxidation
35. Debrisoquine oxidation in a Finnish population: The effect of oral contraceptives on the metabolic ratio
36. Induction of CYP2D6 in pregnancy
37. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping
38. Pregnancy-induced increase in metoprolol metabolism
39. Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism-histograms and probit plots
40. A new, sensitive graphical method for detecting deviations from the normal distribution of drug responses: The NTV plot
41. Polymorphic dextromethorphan metabolism: Cosegregation of oxidative O-demethylation with debrisoquine hydroxylation
42. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine
43. Codeine o-demethylation co-segregates with polymorphic debrisoquine hydroxylation
44. Evidence for the polymorphic oxidation of debrisoquine in the Thai population
45. Salivary analysis for determination of dextromethorphan metabolic phenotype
46. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis
47. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects
48. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
49. CYP2D6 multiallelism
50. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification
51. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population
52. Cytochrome P450 CYP2D6
53. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population
54. Differences in drug metabolism polymorphism between Orientals and Caucasians
55. Inter-individual and inter-ethnic differences in the demethylation and glucuronidation of codeine
56. Pharmacogenetics in biological perspective
57. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs
58. Dextromethorphan O-demethylation polymorphism in an African-American population
59. Metoprolol α-hydroxylation is a poor probe for debrisoquine oxidation (CYP2D6) polymorphism in Jordanians
60. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians
61. Frequent contribution of ultra rapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
62. The debrisoquine hydroxylation gene: A gene of multiple consequences
63. Genetic polymorphism of CYP2D6 in North Indian subjects
64. Genetic polymorphism of CYP2D6 in a Keralite (South India) population
65. Genetic polymorphism of CYP2D6 in Karnataka and Andhra Pradesh population in India
66. Polymorphism of dextromethorphan oxidation in South Indian subjects
67. Reconstruction of human evolution: Bringing together genetic, archaeological and linguistic data
68. Genetic polymorphism of the hepatic cytochrome P4502C19 in North Indian subjects
69. Pharmacogenetics
70. Clinical significance of the sparteine/debrisoquine oxidation polymorphism
71. Pharmacogenetic aspects in the metabolism of psychotropic drugs: Pharmacokinetic and clinical implications
72. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism
73. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: A prospective study
74. 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional genes
75. Pharmacogenetics
76. The hypoalgesic effect of tramadol in relation to CYP2D6
77. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextro-methorphan
78. Codeine and morphine in extensive and poor metabolisers of sparteine: Pharmacokinetics, analgesic effect and side effects
79. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes
80. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype
81. Reducing the risk of drug-drug interactions: A goal of rational drug development
82. Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo
83. Influence of hydroxychloroquine on the bioavailability of oral metoprolol
84. Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors
85. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine?
86. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers
87. Inhibition by fluoxetine of cytochrome P450 2D6 activity
88. CYP2D6 polymorphism in systemic lupus erythematosus patients
89. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility
90. A population-based study of the CYP2D6 and GSTT1 polymorphisms and malignant brain tumors
91. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: A meta-analysis
92. Metabolic polymorphisms in carcinogen metabolising enzymes and cancer susceptibility
93. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine
94. Debrisoquine metabolism in Parkinsonian patients treated with antihistamine drugs
95. Mutant debrisoquine hydroxylation genes in Parkinson's disease
96. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease
97. Genetic polymorphism of CYP2D6 in the Japanese population
98. Absence of effect of seven functional mutations in the CYP2D6 gene in Parkinson's disease
99. Clinical importance of genetic polymorphism of drug oxidation
100. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcome in psychiatry
101. Correlation between cytochrome P-450 CYP2D6 (CYP2D6) genotype and phenotype
102. In vitro approaches can predict human drug metabolism
103. Prediction of CYP2D6-mediated polymorphic drug metabolism (sparteine type) based on in vitro investigations
104. Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: A new avenue for drug discovery
105. A monoclonal antibody inhibitory to human P450 2D6: A paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism
106. Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism
107. Lower prevalence of the debrisoquine oxidative poor metaboliser phenotype in American black versus white subjects
108. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota
109. Inhibition of cytochrome P450 2D6 (CYP2D6) by methadone
110. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians
111. Sparteine metabolism in Canadian Caucasians
112. Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquine and mephenytoin
113. Debrisoquine oxidation in an Australian population
114. Debrisoquine oxidation polymorphism in a Tasmanian population
115. Development of an ELISA to study the polymorphism of dextromethorphan oxidation in a French population
116. Polymorphism of dextromethorphan oxidation in a French population
117. Variability in the frequency of cytochrome P450-2D6 (CYP2D6) deficiency
118. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome
119. Debrisoquine oxidation phenotype during neuroleptic monotherapy
120. Polymorphism of debrisoquine oxidation in New Zealand Caucasian
121. Debrisoquine oxidation polymorphism in a Spanish population
122. Genetic basis for differences in debrisoquine polymorphism between Spanish and other white population
123. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and s-mephenytoin
124. Polymorphic debrisoquine hydroxylation in 757 Swedish subjects
125. Mephenytoin and sparteine oxidation: Genetic polymorphism in Denmark
126. Sparteine oxidation polymorphism in Denmark
127. Polymorphic debrisoquine metabolism in a Turkish population
128. S-mephenytoin, sparteine and debrisoquine oxidation: Genetic polymorphisms in a Turkish population
129. Drug hydroxylator phenotype in Hungary
130. Dextromethorphan O-demethylation polymorphism in the Uruguayan population
131. Polymorphism of debrisoquine hydroxylation among Finns and Lapps
132. Inhibitory effects of neuroleptics on debrisoquine oxidation in man
133. Sparteine oxidation polymorphism in Greenlanders living in Denmark
134. Sparteine and mephenytoin oxidation: Genetic polymorphism in East and West Greenland
135. A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbe Guaymi Amerindians: A case of genetic divergence with tentative phylogenic time frame for the pathway
136. An observation on the ethnic uniqueness of the debrisoquine and sparteine antimodes: A study in the Ngawbe Guaymi Amerindians of Panama
137. The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: Absence of evidence for deficient metaboliser
138. No evidence for the presence of poor metaboliser of sparteine in an Amerindian group: The Cunas of Panama
139. Metoprolol and debrisoquine metabolism in Nigerians: Lack of evidence of polymorphic oxidation
140. Polymorphic hydroxylation of debrisoquine in Nigerians
141. Debrisoquine and metoprolol oxidation in Zambians: A population study
142. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population
143. Debrisoquine hydroxylation polymorphism among Ghanaians and Caucasians
144. Low frequency of dextromethorphan O-demethylation deficiency in a Chinese population
145. Oxidation phenotyping in Chinese and Malay populations
146. Metoprolol oxidation polymorphism in a Korean population: Comparison with native Japanese and Chinese populations
147. Metoprolol and mephenytoin oxidation polymorphism in Far Eastern Oriental subjects: Japanese versus mainland Chinese
148. Frequency of human CYP2D6 mutant alleles in a normal Chinese population
149. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population
150. Metoprolol oxidation in a Japanese population; Evidence for only one poor metaboliser among 262 subjects
151. Evidence of polymorphic oxidation of sparteine in Japanese subjects
152. Debrisoquine and mephenytoin oxidation in Sinhalese: A population study
153. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population
154. The polymorphic 4-hydroxylation of debrisoquin in a Saudi Arabian population
155. Dapson N-acetylation, metoprolol a-hydroxylation and s-mephenytoin 4-hydroxylation polymorphisms in a Indonesian population: A cocktail and extended phenotyping assessment trial
156. Genetic polymorphism of CYP2D6 in Tamil population